



**The Challenge Fund**

Overcoming Cancer in Developing Countries

charity number 1079181

[www.challengefund.org](http://www.challengefund.org)

**The Challenge Fund**  
**Charity number: 1079181**

**Report and Financial Statements**

**for the year ended**

**28th February 2025**

**Wenn Townsend**

Chartered Accountants

**Oxford**

# **The Challenge Fund**

## **Contents**

	<b>Page</b>
Legal and Administrative Information	1
Report of the Trustees	2 - 7
Independent Examiner's Report to the Trustees	8
Statement of Financial Activities	9
Balance Sheet	10
Notes forming part of the Financial Statements	11 -15

## **The Challenge Fund**

### **Legal and Administrative Information**

<b>Charity name:</b>	The Challenge Fund – The Fight Against Cancer in the Emerging World
<b>Charity working name:</b>	The Challenge Fund
<b>Registered charity number:</b>	1079181
<b>Trustees:</b>	Prof. Sir Walter Bodmer (Chair) Mr Geoffrey Niblett Dr. Max Parkin Dr. Anna Rohatiner Dr. Anne Makena Mr Mark Lodge
<b>Executive director:</b>	Vacant
<b>Administrator:</b>	Mrs Biying Liu
<b>Principal office:</b>	Prama House 267 Banbury Road Oxford OX2 7HT
<b>Independent examiner:</b>	Mr Andrew Rodzynski FCA Wenn Townsend – Chartered Accountants 30 St Giles Oxford OX1 3LE
<b>Bankers:</b>	HSBC Private Bank (UK) Limited 8 Canada Square London E14 5HQ

**The Challenge Fund**  
**Report of the Trustees**  
**for the year ended 28th February 2025**

The Trustees present their annual report and financial statements of the charity for the year ended 28th February 2025. The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charity's trust deed, the Charities Act 1993 and the Statement of Recommended Practice: Accounting and Reporting by Charities published in 2005.

**Structure, governance and management**

The Challenge Fund is a registered charity in England and Wales, charity number 1079181.

The Challenge Fund was established by the European School of Oncology (ESO) in 2000 for the purpose of raising funds to support programmes that help fight cancers in developing countries. The management was transferred to the UK office of the International Network for Cancer Treatment and Research (INCTR) in 2007. INCTR was an international, not-for-profit, non-governmental organization in Official Relations with the World Health Organisation and dedicated to helping build capacity for cancer research and treatment in developing countries. INCTR officially ceased to exist as a charity registered in Belgium in 2023.

On appointment, new Trustees sign a model Trustee Declaration Statement committing them to giving their time and expertise. The induction process has been changed to follow the ICSA good practice guide with a formal induction programme for any newly-appointed Trustee, which includes an initial meeting with the Chair and the Trustees, followed by a series of short meetings with the Director on fundraising, promotion and responsibilities of the Trustee board. The welcome pack includes a brief history of the Charity, a copy of the membership list of the Board of Trustees, a copy of the most recent annual report and accounts, a copy of the governing trust deed and a copy of the Charity Commission's guidance 'The Essential Trustee: What You Need to Know' and Charities and Public Benefit'. The Trustees, director and administrator give their time freely and no remuneration was paid in the year.

The Charity treats Data Protection matters seriously. Following the call for the General Data Protection Regulation (EU) 2016/679 in early 2018, The Challenge Fund registered itself voluntarily with the Office of the Information Commissioner under registration number **A8405014**, with the Data Controller being Ms Biying Liu (Administrator). A [Privacy Policy document](#) and a [Consent Form](#) were developed and are available on the charity website.

**Objectives and activities for the public benefit**

The Challenge Fund currently supports projects approved by the Board of Trustees of the charity that improve the healthcare delivered to cancer patients in low- and middle-income countries and help reduce their suffering by:

- \* Providing cancer treatment resources, including chemotherapy drugs and anti-bacterial drugs for patients with Burkitt Lymphoma in Africa.
- \* Training local nurses, doctors and healthcare providers in cancer treatment, palliative care and cancer registration.
- \* Providing effective palliative care services for terminally ill cancer patients in Nepal.
- \* Improving the effectiveness of cancer surveillance in sub-Saharan Africa by providing expert evaluation and technical support to remedy identified barriers, with the long-term goals of strengthening health systems and creating research platforms for the identification of problems, priorities, and targets for intervention.
- \* Providing international communication platform for advocacy, knowledge sharing and promotion for health related projects.

## **The Challenge Fund**

### **Report of the Trustees for the year ended 28th February 2025**

#### **Policy of accepting projects of the charity**

The Charity has established its grant-making policy to achieve its objects for the public benefit to improve the lives of sufferers with cancers who live in Low- and Middle-Income Countries (LMIC). The beneficiaries of our grant-making programme are cancer patients and front-line health workers in countries where the projects (listed below) are being carried out.

Cancer is a leading cause of death worldwide accounting for the deaths of nearly 10 million people in 2020<sup>1</sup>; approximately 70% of which occur in low- and middle- income countries. Globally, cancer is killing more people in low- and middle-income countries than HIV/AIDS, Malaria and Tuberculosis combined, at an average rate of ten deaths a minute.

Over 19 million new cases of cancer were diagnosed in 2020; the number of new cancer cases is expected to increase more than 76% in low- and mid- income countries by 2040. 80% of patients with cancer in low- and middle-income countries are only diagnosed when their cancers are too advanced for curative treatment. In many of these countries there is little or no access to effective pain relief. As a result, cancer patients and their families have to endure terrible suffering.

The need to carefully plan cancer services in Africa is well recognised, in view of the limited resources available to combat the rising tide of non-communicable diseases, and especially cancer. Rational planning should rely on accurate data from within the country. Population-based cancer registries can provide the fundamental information on cancer incidence, trends, survival, and estimates on mortality and prevalence.

The Charity invites applications for research grants and educational grants. Eligibility is restricted to applicants who have expertise in the field and are operating projects in LMICs, either from the UK or in the countries concerned.

#### **Procedures of accepting a new project**

A potential applicant would be invited to submit a copy of his/her curriculum vitae, along with a copy of a completed New Project Application Form. The Form contains a summary of the project that the applicant wishes to operate under the mechanism of the charity.

The Board of Trustees will discuss and give any necessary instructions for the next step. Should the trustees consider that the project is suitable, they would invite the candidate for a meeting (either in person or virtual) to clarify any remaining queries.

A final decision is determined by a meeting of the Trustees. The applicant would be informed of the decision within 10 working days.

#### **How our grants and research programmes delivered public benefit in March 2024- February 2025**

##### ***A. The Nepal Hospice Project supports the development of a palliative care centre in Kathmandu, Nepal.***

The Two Worlds Cancer Collaboration Foundation (TWCC) was established as a Canadian registered society and charitable foundation in 2011 for the provision of strategy, infrastructure and funding to support the existing palliative care (PAX) programme, and to enable expansion of its activities in Hyderabad (Nepal) and other global jurisdictions.

---

<sup>1</sup> International Agency for Research on Cancer, Cancer Today <https://gco.iarc.fr/today/home>

**The Challenge Fund**  
**Report of the Trustees**  
**for the year ended 28th February 2025**

The beneficiaries of the PAX programme are terminally ill cancer patients and their families, and the palliative care health providers in Nepal. As part of the programme, one of the main objectives of the Project is to build a new palliative care centre to provide quality cancer care to terminally ill patients, and tailored education to doctors and nurses in Nepal.

In 2024, the Hospice Project (<https://www.hospicenepal.com>) team in the UK, led by Emily Brown, continued to raise funds towards the building of the Hospice through donations.

The money raised for the Hospice Nepal Project is ring-fenced and hosted in the charity accounts until funding requests are received and approved by the Trustees.

The plan for 2025 involves partnering with Rotary to continue to raise funds towards the Hospice Project as well as obtaining donations from individuals and/or organisations to further this goal.

- B.** The African Cancer Registry Programme (AFCRN) partnered with the International Agency for Research on Cancer in the framework of the Global Initiative for Cancer Registry Development in Low- and Middle-Income Countries (GICR) to provide a network Regional Hub for cancer registration in Sub-Saharan Africa (SSA).

The beneficiaries of the AFCRN programme are the population-based cancer registries (PBCRs) in SSA and the users of the data produced by these PBCRs.

During 2024, the Network supported a membership of 35 members across 24 SSA countries. The most significant activities during the year were:-

- Education – completion of the e-learning project, supported by Vital Strategies (Bloomberg Data for Health Initiative) in collaboration with WHO/IARC and a cadre of teaching experts based in SSA.
- In collaboration with McCabe and IARC, the legal template and guideline for ‘making cancer a reportable disease’ is being finalised.
- Capacity building – The Bloomberg Data for Health Initiative via its research agency Vital Strategies continued to support the three IARC-GICR Collaborating Centres in SSA. They are the training centre in Kenya, research centre in South Africa and the centre for technical support and training for Francophone countries in Cote d’Ivoire and in Angola for Lusophone countries.
- Development – Three ongoing country-level programmes in Tanzania, Mozambique, and Zimbabwe are planned to last for 5 years.
- Technology – DHIS2 oncology module developed in Rwanda, assessment has been done during 2024. Its experience will be shared with fellow countries during 2025.

The AFCRN database was updated during 2024. The data were used for the national estimates of cancer incidence and mortality “GloboCan 2024” (the official statistical data of WHO) and datasets are being assessed for the new IARC publication “Cancer Incidence in Five Continents”, Vol 13.

**C. London Global Cancer Week (LGCW)**

The Charity’s UK advocacy began in 2016 with events held at Oxford Town Hall, as part of the charity’s promotion and fundraising activities. Since 2020, the Charity has provided support for the annual London Global Cancer Week (LGCW) conference, which yearly has attracted increasingly larger attendance and substantial external funding.

The purpose of LGCW is to promote activities for improving healthcare for cancer patients in developing countries both in the UK and in LMICs. The nature of the event is a series of meetings, webinars, discussion

**The Challenge Fund**  
**Report of the Trustees**  
**for the year ended 28th February 2025**

and workshops within a fixed timeframe (one week). The main PIs for LGCW are Mr Mark Lodge and Dr Susannah Stanway.

The 6th London Global Cancer Week conference (11-15 November 2024) presented 43 events drawing an audience of >2000 attendees from 122 countries. Convened by Susannah Stanway and Katie Wakeham, the conference successfully featured a mix of in-person, hybrid and virtual events focused on a wide range of cancer control issues, and hosted by WHO, NCI Centre for Global Health, The Commonwealth and other organisations. On Wednesday 13 November a Round Table meeting of international experts discussed Financing Global Cancer Control. The Week ended with a full one-day meeting at the House of Commons entitled “Cancer Health Disparities: Understanding the inequalities conundrum”.

The test for each LGCW is how successfully it has shared knowledge and provided the opportunity for new developments and positive change. LGCW 2024 provided a platform for a presentation on Cancer Surveillance in sub-Saharan Africa featuring the work of the African Cancer Registry Network, a key project supported by the Charity. (This session is viewable at <https://www.lgcw.org.uk/watch-again/>) The conference included an influential Round Table discussion on Building Health Care Systems Resilience in Low and Middle Income Countries; a summary of which is published in Cancer Control 2024 (ref: <https://www.cancercontrol.info/wp-content/uploads/2024/10/24-27-roundtable.pdf>).

**D. UK Ireland Global Cancer Network (UKIGCN)**

The UKIGCN is a new project being accepted by the Board of the charity during its Annual Trustee’s Meeting in February 2025. Details of the project are to be developed during 2025.

**E. The INCTR Burkitt lymphoma (BL) treatment programme provides chemotherapy drugs and healthcare to children with BL in Africa.**

Burkitt lymphoma is one of the most common childhood cancers in equatorial Africa, accounting for up to 50% of all paediatric cancer in some regions. Most families cannot afford the cost of treatment or even travel to a centre capable of providing care. Yet the disease is highly curable, even when resources are limited.

The INCTR BL programme began in 2004. The programme aims to provide cancer treatment drugs and care, free to eligible patients. The programme also covered some side-effect treatments such as antibiotic drugs. With the passing of Dr Ian Magrath and Mrs Melissa Adde [March 2023], the INCTR has been wound up. The Active Members and Governing Council of INCTR decided that Ca\$105,000 should be transferred to the charity The Challenge Fund, to be used for the treatment and care of children with BL in the three centres formerly part of the INCTR BL project.

**Monitoring achievement**

The success of the PHN programme is evaluated by the increased number of nurses and medical staff being educated by the programme and with an increase in the number of patients being helped by the team. The goal in 2024 was to raise sufficient funds to start the construction of the hospice; this was achieved and construction is underway.

The overall goal of the **AFCRN** is to increase coverage of high quality cancer registration in the SSA countries. The success of the AFCRN activities is evaluated in terms of the number of registries and the number of countries with a cancer registry, their data quality and comprehensiveness, and the use of their data.

The indicator of a success of the **LGCW** event is the number of organisations contributing to the LGCW, and the impact from the event, and the activities resulting from it.

**The Challenge Fund**  
**Report of the Trustees**  
**for the year ended 28th February 2025**

**Trustees' Meeting**

There was one board meeting during this financial year (Feb 2024).

Matters arising.

The Executive Director role is still vacant. The post is on voluntary basis, the charity is yet to identify a new candidate for the position.

No changes to the Trustee Board during 2024.

The trustees agreed that the charity would continue to ring-fence the existing funding for BL, and supported restarting the programme following the clarification of certain remaining funding issues.

The Board also wished to start a new project either by adapting one or developing one within the charity. The matter will depend on the recruitment of a new Executive Director.

**Financial review**

The Charity's work is partly reliant on individual donations, fundraising by volunteers and, partly on the receipt of restricted grants from other donors.

**BL**

The secretary reported that income raised during the period was £60,418 for the BL programme. Geoffrey Niblett confirmed that the CNMF will continue to raise funds to support activities directed at the treatment and support of children with Burkitt lymphoma.

**PAX**

In 2024, the Nepal Hospice UK team raised £276.

**AFCRN**

AFCRN activities were mainly funded by the Bloomberg Data for Health Initiative via its research agency the Vital Strategies in the USA and via research grants provided by the Martin Luther University Halle-Wittenberg and the International Agency for Research on Cancer. The main expenditure of this funding was data collection for research projects, support of the development of cancer registries in SSA, and travel for consultancy and training purposes. The total income for the programme in 2024 was £188,775. Overheads on grants received for the programme were used to finance the running costs of the charity.

**LGCW**

Via the 2024 event, LGCW raised £39,753 through sponsorship and donations.

## **The Challenge Fund**

### **Report of the Trustees for the year ended 28th February 2025**

#### **Reserves policy**

The Trustees aim to maintain free reserves in unrestricted funds at a level which equates to approximately three months of unrestricted charitable expenditure. The Trustees consider that this level will provide sufficient funds to respond to applications for grants and ensure that there are sufficient funds available to cover support and governance costs. It is considered that a level of 3 months is sufficient.

The balance held as unrestricted funds at 28th February 2025 was a surplus of £4,272 against an actual 3 month spending of £200 for rent. The current level of reserves is therefore higher than is needed.

#### **Plans for the future**

The Charity will continue to support the programmes described above in the next financial year.

This report was approved by the Board on ...17th Dec..... 2025 and signed on its behalf by



**Prof. Sir Walter Bodmer**  
Trustee

## **The Challenge Fund**

### **Independent Examiner's Report to the Trustees of 28th February 2025**

I report to the charity trustees on my examination of the accounts of the charity for the year ended 28th February 2025 which are set out on pages 9 to 15.

#### **Responsibilities and basis of report**

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

#### **Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



**Andrew Rodzynski FCA**  
**For and on behalf of Wenn Townsend**  
**Chartered Accountants, 30 St Giles, Oxford OX1 3LE**

.....7 January 2026.....

## The Challenge Fund

### Statement of Financial Activities for the year ended 28th February 2025

	Notes	Unrestricted funds £	Restricted funds £	Total 2025 £	Unrestricted funds £	Restricted funds £	Total 2024 £
<b>Income</b>							
Donations		-	8,753	8,753	74	111,131	111,205
Investment income	3	1,178	-	1,178	1,481	-	1,481
Charitable activities	2	-	280,469	280,469	-	70,946	70,946
Other income		-	-	-	-	-	-
<b>Total income</b>		<u>1,178</u>	<u>289,222</u>	<u>290,400</u>	<u>1,555</u>	<u>182,077</u>	<u>183,632</u>
<b>Expenditure</b>							
Charitable activities	4	<u>9</u>	<u>328,895</u>	<u>328,904</u>	<u>35</u>	<u>304,592</u>	<u>304,627</u>
<b>Total expenditure</b>		<u>9</u>	<u>328,895</u>	<u>328,904</u>	<u>35</u>	<u>304,592</u>	<u>304,627</u>
<b>Net income/(expenditure)</b>		1,169	(39,673)	(38,504)	1,520	(122,515)	(120,995)
Fund balances brought forward at 1st March 2024		<u>3,103</u>	<u>130,081</u>	<u>133,184</u>	<u>1,583</u>	<u>252,596</u>	<u>254,179</u>
<b>Fund balances carried forward at 28th February 2025</b>		<u><u>4,272</u></u>	<u><u>90,408</u></u>	<u><u>94,680</u></u>	<u><u>3,103</u></u>	<u><u>130,081</u></u>	<u><u>133,184</u></u>

The notes on pages 11 to 15 form an integral part of these financial statements

# The Challenge Fund

## Balance Sheet as at 28th February 2025

	Notes	2025	2024
		£	£
<b>Non current assets</b>			
Computer equipment	7	-	-
<b>Current assets</b>			
Debtors		66,912	17,729
Cash at bank		235,508	293,369
		<u>302,420</u>	<u>311,098</u>
<b>Creditors:</b> amounts falling due within one year	8	<u>(207,740)</u>	<u>(177,914)</u>
<b>Net current assets</b>		<u>94,680</u>	<u>133,184</u>
<b>Net assets</b>		<u><u>94,680</u></u>	<u><u>133,184</u></u>
<b>Unrestricted funds</b>		4,272	3,103
<b>Restricted funds</b>	9	<u>90,408</u>	<u>130,081</u>
		<u><u>94,680</u></u>	<u><u>133,184</u></u>

The financial statements were approved and authorised for issue by the Trustees on ..... 2025 and signed on their behalf by:

.....  
**Prof. Sir Walter Bodmer**  
**Trustee**

The notes on pages 11 to 15 form an integral part of these financial statements

## The Challenge Fund

### Notes to the Accounts for the year ended 28th February 2025

#### 1 Accounting policies

##### (a) Basis of preparation

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

##### (b) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes. Restricted funds are where the funds have been specified as for use for a particular project.

##### (c) Income

All income is included in the SOFA when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Income from investments is credited in the period in which it is receivable.

##### (d) Expenditure

All expenditure is accounted for on an accruals basis. All expenses, including support costs and governance costs are allocated or apportioned to the applicable expenditure headings in the statement of financial activities.

##### (e) Debtors and creditors receivable/payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price.

##### (f) Going concern

The financial statements have been prepared on a going concern basis as the trustees believe no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements.

##### (g) Fixed assets

Expenditure on fixed assets is capitalised. Depreciation is calculated to write off the cost of tangible fixed assets over their expected useful lives as follows:

Furniture and equipment	25%	Straight line
-------------------------	-----	---------------

#### 2. Income from charitable activities

	2025 £	2024 £
Grants	280,469	70,946

**The Challenge Fund**  
**Notes to the Accounts**  
**for the year ended 28th February 2025**

..... continued

**3. Investment income**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Interest receivable	1,178	1,481
	<u>1,178</u>	<u>1,481</u>

**4. Charitable expenditure**

	<b>AFCRN</b>	<b>BL</b>	<b>PAX</b>	<b>LGCW</b>	<b>Total</b>	<b>Un-</b>	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>restricted</b>	<b>restricted</b>	<b>£</b>	<b>£</b>
<b>Restricted</b>								
Administrative costs	27,900	-	-	-	27,900	-	27,900	26,170
Research co-ordination costs	6,315	-	-	-	6,315	-	6,315	11,645
Consultancy	11,238	-	-	50,012	61,250	-	61,250	72,031
Meetings	56,813	-	-	-	56,813	-	56,813	82,304
Training	1,041	-	-	-	1,041	-	1,041	852
MoU agreement	77,157	-	-	-	77,157	-	77,157	95,160
Grants	-	9,000	73,000	3,088	85,088	-	85,088	-
Bank charges	767	-	1,157	106	2,030	-	2,030	1,081
Support costs (note 5)	11,301	-	-	-	11,301	9	11,310	15,384
	<u>192,532</u>	<u>9,000</u>	<u>74,157</u>	<u>53,206</u>	<u>328,895</u>	<u>9</u>	<u>328,904</u>	<u>304,627</u>

**5. Support costs**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Rent	725	790
Promotion	-	-
Travel, subsistence and accommodation	2,929	3,176
Website costs	173	1,310
Bank charges	484	192
Sundries	40	35
Exchange difference	5,092	6,707
Governance costs (see note 5a)	1,867	3,174
Depreciation expense	-	-
	<u>11,310</u>	<u>15,384</u>

**5 (a) Governance costs**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Independent examiner's fees	1,832	3,174
Trustee meetings	-	-
	<u>1,832</u>	<u>3,174</u>

**The Challenge Fund**  
**Notes to the Accounts**  
**for the year ended 28th February 2025**

..... continued

**6. Related party transactions**

The Trustees neither received any emoluments nor reimbursed expenses during the year (2024: £Nil).

There were no related party transactions in the current or preceding year.

**7. Tangible fixed assets**

	<b>Computer Equipment</b> <b>£</b>
Cost b/fwd and c/fwd	1,137
	<hr/>
Depreciation b/fwd	1,137
Depreciation charge for the year	-
	<hr/>
Depreciation c/fwd	1,137
	<hr/>
Net book value at 28th February 2025	-
	<hr/> <hr/>
Net book value at 29th February 2024	-
	<hr/> <hr/>

**8. Creditors: amounts falling due within one year**

	<b>2025</b> <b>£</b>	<b>2024</b> <b>£</b>
Independent examiner's fees accrued	2,320	5,264
Deferred grant income	205,420	172,650
	<hr/>	<hr/>
	207,740	177,914
	<hr/> <hr/>	<hr/> <hr/>

**The Challenge Fund**  
**Notes to the Accounts**  
**for the year ended 28th February 2025**

..... continued

**9. Restricted funds – current year**

	Balance at 1st March 2024 £	Income £	Expenditure £	Transfer between funds £	Balance at 28th February 2025 £
The African Cancer Registry Network	19,220	188,775	(192,532)	-	15,463
Palliative Care Access programme	75,819	276	(74,157)	-	1,938
Burkitt Lymphoma	13,145	60,418	(9,000)	-	64,563
LGCW	21,897	39,753	(53,206)	-	8,444
	<u>130,081</u>	<u>289,222</u>	<u>(328,895)</u>	<u>-</u>	<u>90,408</u>

**Restricted funds – prior year**

	Balance at 1st March 2023 (restated) £	Income £	Expenditure £	Transfer between funds £	Balance at 29th February 2024 (restated) £
The African Cancer Registry Network	199,482	71,001	(251,263)	-	19,220
Palliative Care Access programme	38,451	38,450	(1,082)	-	75,819
Burkitt Lymphoma	8,043	5,102	-	-	13,145
LGCW	6,620	67,524	(52,247)	-	21,897
	<u>232,538</u>	<u>182,022</u>	<u>(304,592)</u>	<u>-</u>	<u>130,081</u>

The split of income between funds brought forward in the prior year has been restated to correct errors in allocation. The corrected balances have been brought forward to the current year. There has been no effect on total income, surplus for the year or net assets from this change.

The Report of the Trustees on pages 2-7 provides further information on each restricted fund held.

**The Challenge Fund**  
**Notes to the Accounts**  
**for the year ended 28th February 2025**

..... continued

**10. Analysis of funds – current year**

	<b>Restricted £</b>	<b>Unrestricted £</b>	<b>Total £</b>
Tangible assets	-	-	-
Debtors	66,912	-	66,912
Bank and cash	231,236	4,272	235,508
Creditors	(207,740)	-	(207,740)
	<u>90,408</u>	<u>4,272</u>	<u>94,680</u>
	<u><u>90,408</u></u>	<u><u>4,272</u></u>	<u><u>94,680</u></u>

**Analysis of funds – prior year**

	<b>Restricted £</b>	<b>Unrestricted £</b>	<b>Total £</b>
Tangible assets	-	-	-
Debtors	17,729	-	17,729
Bank and cash	290,266	3,103	293,369
Creditors	(177,914)	-	(177,914)
	<u>130,081</u>	<u>3,103</u>	<u>133,184</u>
	<u><u>130,081</u></u>	<u><u>3,103</u></u>	<u><u>133,184</u></u>